Effects of Atorvastatin (10 mg) on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically proven coronary artery disease

American Journal of Cardiology

Volumn 94, Issue 2, 2004, Pages 206-209

  Tekin, Abdullah ^a   Tekin, Göknur ^a   Güzelsoy, Deniz ^b   Kaya, Ayşem ^b   Gürel, Çiǧdem Vural ^b   Yiǧit, Zerrin ^b   Ulutin, Turgut ^b  

^a BASKENT UNIVERSITY   (Turkey)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ATORVASTATIN; C REACTIVE PROTEIN; FIBRINOGEN; LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR ANTIGEN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; HEMOSTASIS; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; MALE; PARAMETER; PATIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; COMORBIDITY; CORONARY ANGIOGRAPHY; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; FEMALE; HEMOSTASIS; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; PROTHROMBIN; PYRROLES; TISSUE PLASMINOGEN ACTIVATOR;

EID: 3142638795     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.03.065     Document Type: Article

References (19)

1. Rosenson R.S., Tangney C.C. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. JAMA. 279:1998;1643-1650
2. Seljeflot I., Tonstad S., Hjermann I., Arnesen H. Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb Res. 105:2002;285-290
3. Joukhadar C., Klein N., Prinz M., Schrolnberger C., Vukovich T., Wolzt M., Schmetterer L., Dorner G.T. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost. 85:2000;47-51
4. Dujovne C.A., Harris W.S., Altman R., Overhiser R.W., Black D.M. Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. Am J Cardiol. 85:2000;350-353
5. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957;17:237-246
6. Lopez S., Peiretti F., Bonardo B., Juhan-Vague I., Nalbone G. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis. 152:2000;359-366
7. Bourcier T., Libby P. HMG CoA reductase inhibitors reduce plasminogen activator 1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol. 20:2000;556-562
8. Latron Y., Chautan F., Anfosso M.C., Nalbone G., Lafront H., Juhan-Vague I. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb. 11:1991;1821-1829
9. Sticko-Rahm A., Wiman B., Hamsten A., Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis. 10:1990;1067-1073
10. Dangas G., Badimon J.J., Smith D.A., Unger A.H., Levine D., Shao J.H., Meraj P., Fier C., Fallon J.T., Ambrose J.A. Pravastatin therapy in hyperlipidemia effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol. 33:1999;1294-1304
11. Dangas G., Smith D.A., Badimon J.J., Unger A.H., Shao J.H., Meraj P., Cohen A.M., Levine D., Fallon J.T., Ambrose J.A. Gender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatin. Am J Cardiol. 84:1999;639-643
12. Isaacsohn J.L., Setaro J.F., Nicholas C., Davey J.A., Diotalevi L.J., Christianson D.S., Liskov E., Stein E.A., Black H.R. Effects of lovastatin therapy on plasminogen activator-1 antigen levels. Am J Cardiol. 74:1994;735-737
13. Thompson S.G., van de Loo J.C. ECAT Angina Pectoris Study. Baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J. 14:1993;8-17
14. Mussoni L., Manucci I., Marina S., Camera M., Maderna P., Sironi L., Tremoli E. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb. 12:1992;19-27
15. Thompson S.G., Kienast J., Pyke S.D., Haverkate F., van de Loo J.C. The European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 332:1995;635-641
16. Schumacher A., Seljeflot I., Sommervoll L., Christensen B., Otterstad J.E., Arnesen H. Increased levels of endothelial haemostatic markers in patients with coronary heart disease. Thromb Res. 105:2002;25-31
17. Ridker P.M., Vaughan D.E., Stampfer M.J., Manson J.E., Hennekens C.H. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 341:1993;1165-1168
18. Hamsten A., de Faire U., Walldius G., Dahlen G., Szamosi A., Landou C., Blomback M., Wiman B. Plasminogen activator inhibitor in plasma risk factor for recurrent myocardial infarction. Lancet. 2:1987;3-9
19. Juhan-Vague I., Valadier J., Alessi M.C. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep vein thrombosis. Thromb Haemost. 57:1987;67-72